Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 16/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13578880 | 0.84 | KMT2A (0.43) | WDR5KMT2ACRHR1 | |
| SCHEMBL5496929 | 0.79 | CRHR1 (0.40) | KMT2ACRHR1 | |
| SCHEMBL4326988 | 0.79 | CRHR1 (0.38) | WDR5KMT2ACRHR1 | |
| SCHEMBL6291133 | 0.78 | CRHR1 (0.58) | CRHR1 | |
| SCHEMBL6295002 | 0.78 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL8042350 | 0.77 | P2RX4 (0.36) | KMT2ACRHR1 | |
| SCHEMBL6295000 | 0.76 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL5492382 | 0.75 | CRHR1 (0.36) | CRHR1 | |
| SCHEMBL18000045 | 0.73 | ALDH1A1 (0.46) | WDR5KMT2A | |
| SCHEMBL8032963 | 0.72 | CRHR1 (0.36) | WDR5KMT2ACRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074929-B2 | Certain alkylene diamine-substituted heterocycles | NEUROGEN CORP. (US) | 2006-07-11 | — | — | US | disclosed |
| US-6869955-B2 | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040229870-A1 | Certain alkylene diamine-substituted heterocycles | NEUROGEN CORPORATION | 2004-11-18 | — | — | US | disclosed |
| US-6696445-B2 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS COMPRISING HETEROCYCLIC NITROGEN COMPOUNDS AND/OR PRODRUGS USED FOR PROPHYLAXIS OF EATING AND CARDIOVASCULAR DISORDERS | NEUROGEN CORPORATION | 2004-02-24 | — | — | US | disclosed |
| EP-1380298-A2 | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders, anorexia, inflammation | Bristol-Myers Squibb Pharma Company (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-0901374-B1 | TETRAHYDROPTERIDINES AND PYRIDYLPIPERAZINES FOR TREATMENT OF NEUROLOGICAL DISORDERS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030158197-A1 | Certain alkylene diamine-substituted heterocycles | NEUROGEN CORPORATION | 2003-08-21 | — | — | US | disclosed |
| US-20030064993-A1 | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders | WILDE RICHARD GERALD (US) | 2003-04-03 | — | — | US | disclosed |
| US-6506762-B1 | Mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. Novel compounds are for eating | NEUROGEN CORPORATION | 2003-01-14 | — | — | US | disclosed |
| US-6448261-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS; TREATING ANXIETY, DEPRESSION, AND OTHER PSYCHIATRIC AND NEUROLOGICAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-0935601-A4 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | DU PONT PHARM CO (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1224187-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES | NEUROGEN CORPORATION (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6399609-B1 | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-04 | — | — | US | disclosed |
| WO-2001023389-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| US-6107300-A | CORTICOTROPIN RELEASING FACTOR ANTAGONIST; PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS (US) | 2000-08-22 | — | — | US | disclosed |
| US-6083948-A | TREATING ANXIETY, DEPRESSION, AND OTHER PSYCHIATRIC AND NEUROLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| CN-1230184-A | Arylamino fused pyridines and pyrimidines | DU PONT MERCK PHARMA (US) | 1999-09-29 | — | — | CN | disclosed |
| EP-0935601-A2 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | Du Pont Pharmaceuticals Company (US) | 1999-08-18 | — | — | EP | disclosed |
| WO-1997035539-A2 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | DU PONT PHARMACEUTICALS COMPANY (US) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064993-A1 | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders | CRH, CRHR1, CRHR2 | WDR5 1546/4885KMT2A 3922/4885CRHR1 2/4885 |
| US-20030158197-A1 | Certain alkylene diamine-substituted heterocycles | NPY1R, NPY5R, NPY2R | WDR5 1272/4885KMT2A 1794/4885CRHR1 16/4885 |
| US-20040229870-A1 | Certain alkylene diamine-substituted heterocycles | NPY1R, NPY5R, NPY2R | WDR5 1166/4885KMT2A 1514/4885CRHR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.